VEGFA and hereditary hemorrhagic telangiectasia: Recently, indirect inhibitors of VEGF signaling such as pazopanib (inhibits various tyrosine kinase receptors such as VEGFR2) (65) and thalidomides were experimented in a small number of patients with HHT with some early success in reducing bleeding (64, 66).